Pelvic Mesothelioma Tumor Shrinks 83% With Immunotherapy in Rare Case Report
Frontiers in Oncology case study shows toripalimab plus chemotherapy produced major tumor reduction in rare pelvic mesothelioma.
Articles by James
Durvalumab Plus Chemotherapy Doubles Median Survival to 20 Months in Mesothelioma Trial
Phase II PrE0505 trial shows durvalumab with pemetrexed-cisplatin yields 20.4-month median survival in unresectable pleural mesothelioma.
UK Trial Tests Proton Beam Therapy for Mesothelioma, Targeting 50% Two-Year Survival
Phase III HIT-Meso trial compares proton beam therapy to surveillance across 25 UK centers, recruiting 148 people with pleural mesothelioma.
University of Hawaii Identifies L-BAM, a Treatable Form of Mesothelioma
UH Cancer Center researchers discover a genetic mesothelioma variant caused by BAP1 mutations, not asbestos, that responds to standard treatment.
CheckMate-743 at Five Years: 14% of People on Immunotherapy Still Alive
Five-year data from CheckMate-743 shows 14% survival with nivolumab plus ipilimumab vs 6% with chemotherapy. Non-epithelioid benefit is striking.
DREAM3R Phase 3 Trial: Durvalumab Plus Chemo Shows Signals but Falls Short of Proof
DREAM3R Phase 3 trial of durvalumab plus chemotherapy for pleural mesothelioma stopped early due to enrollment challenges. A 58% response rate, but no proof.
Baylor-Duke Trial Tests Immunotherapy Plus Chemo Before Mesothelioma Surgery
NEMO trial at Baylor and Duke is recruiting people with operable pleural mesothelioma to test chemoimmunotherapy before surgery.
Blood Test Predicts Immunotherapy Response in Operable Mesothelioma
Georgetown-Hopkins Phase 2 trial shows ctDNA blood test predicts which mesothelioma patients benefit from immunotherapy before surgery.
Mount Sinai P/D Surgery Achieves Zero Mortality in Mesothelioma Study
Mount Sinai reports zero perioperative mortality for pleurectomy/decortication in mesothelioma, challenging MARS2 trial skepticism.
UCSF Proposes First Staging System for Peritoneal Mesothelioma
Dr. Mohamed Adam's survival tree model uses mitotic rate, PCI, and histology to stage peritoneal mesothelioma and guide CRS-HIPEC decisions.
Checkpoint Inhibitors for Mesothelioma: FDA-Approved Options and How They Work
FDA-approved nivolumab plus ipilimumab improves mesothelioma survival. Learn how checkpoint inhibitors work, side effects, and who benefits.
Genetic Testing for Mesothelioma: Types, Benefits, and What Results Mean
Genetic testing for mesothelioma including BAP1, CDKN2A, and NGS panels. How results guide treatment decisions and clinical trial eligibility.
Rare Mesothelioma Cell Types: Variants, Prognosis, and Treatment
Rare mesothelioma cell types: desmoplastic, lymphohistiocytoid, deciduoid, and WDPM variants. Diagnosis challenges and prognosis.
Targeted Therapy for Mesothelioma: Precision Medicine Options
Targeted therapy options for mesothelioma including BAP1, NF2, and TEAD inhibitors. Current clinical trials and who may benefit.
ADI-PEG20 Phase 3 Trial Shows Promise: ATOMIC-Meso Results
ATOMIC-Meso Phase 3 trial shows ADI-PEG20 plus chemotherapy improves survival in pleural mesothelioma. Analysis of this arginine-depleting therapy.
TEAD Inhibitor IK-930 Shows Activity in Mesothelioma: ESMO Update
TEAD inhibitor IK-930 shows clinical activity in NF2-mutated mesothelioma at ESMO. First targeted therapy for this genetic subtype.
UV1 Cancer Vaccine Receives FDA Fast Track for Mesothelioma
FDA grants Fast Track to UV1 telomerase vaccine for mesothelioma. Combined with immunotherapy, UV1 showed 64% response rate in trials.
Atezolizumab Phase 3 Trial for Pleural Mesothelioma
PHASE3 clinical trial testing atezolizumab (Tecentriq) for mesothelioma. Trial NCT04996017 is recruiting.
Atezolizumab Trial: Phase 1 Study for Mesothelioma
Cancer Research UK PHASE1/PHASE2 clinical trial testing atezolizumab (Tecentriq) for people with mesothelioma. Trial NCT05944237 is now recruiting.
Atezolizumab Phase 1 Trial for Pleural Mesothelioma
University Hospital, Antwerp PHASE1/PHASE2 clinical trial testing atezolizumab (Tecentriq) for people with mesothelioma. Trial NCT05765084 is now recruiting.
CAR-T Trial NCT04981119 (A2 Biotherapeutics): Screening Study for Mesothelioma
A2 Biotherapeutics Inc. N/A clinical trial testing CAR-T cell therapy for people with mesothelioma. Trial NCT04981119 is now recruiting.
CAR-T Trial NCT06051695 (A2 Biotherapeutics): Phase 1/2 Study for Mesothelioma
A2 Biotherapeutics Inc. PHASE1/PHASE2 clinical trial testing CAR-T cell therapy for people with mesothelioma. Trial NCT06051695 is now recruiting.
CAR-T Trial NCT06256055 (UTC Therapeutics): Phase 1 Study for Mesothelioma
UTC Therapeutics Inc. PHASE1 clinical trial testing CAR-T cell therapy for people with mesothelioma. Trial NCT06256055 is now recruiting.
CAR-T Trial NCT06885697 (NCI): Phase 1 Study for Mesothelioma
National Cancer Institute (NCI) PHASE1 clinical trial testing CAR-T cell therapy for people with mesothelioma. Trial NCT06885697 is now recruiting.
CAR-T Trial: Phase 1 Study for Pleural Mesothelioma
Suzhou Maximum Bio-tech Co. Ltd. PHASE1 clinical trial testing CAR-T cell therapy for people with mesothelioma. Trial NCT06726564 is now recruiting.
Immunotherapy Trial: Phase 1 Study for Mesothelioma
Baylor College of Medicine PHASE1/PHASE2 clinical trial testing immunotherapy for people with mesothelioma. Trial NCT05932199 is now recruiting.
HIPEC Trial NCT05001880 (NCI): Phase 2 Study for Peritoneal Mesothelioma
PHASE2 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT05001880 is recruiting.
HIPEC Trial NCT04847063 (NCI): Phase 1 Study for Peritoneal Mesothelioma
PHASE1 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT04847063 is recruiting.
HIPEC Trial NCT06057935 (Memorial Sloan Kettering): Phase 2 Study for Peritoneal Mesothelioma
PHASE2 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT06057935 is recruiting.
Immunotherapy Trial NCT03935893 (Udai Kammula): Phase 2 Study for Mesothelioma
Udai Kammula PHASE2 clinical trial testing immunotherapy for mesothelioma patients. Trial NCT03935893 is now recruiting.
Immunotherapy Trial NCT05730816 (Brigham & Women's): Phase 2 Study for Mesothelioma
Brigham and Women's Hospital PHASE2 clinical trial testing immunotherapy for people with mesothelioma. Trial NCT05730816 is now recruiting.
Immunotherapy Trial NCT06477419 (MSK): Phase 2 Study for Mesothelioma
Memorial Sloan Kettering Cancer Center PHASE2 clinical trial testing immunotherapy for people with mesothelioma. Trial NCT06477419 is now recruiting.
Immunotherapy Trial NCT06503146 (NCI): Phase 2 Study for Mesothelioma
National Cancer Institute (NCI) PHASE2 clinical trial testing immunotherapy for people with mesothelioma. Trial NCT06503146 is now recruiting.
92 Mesothelioma Clinical Trials Recruiting Now: What's Being Tested in 2026
92 mesothelioma trials recruiting now. Immunotherapy leads with 32 trials, CAR-T emerges with 5. Complete 2026 data by state, phase, and treatment type.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT04665206)
Vivace Therapeutics, Inc PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT04665206 is now recruiting.
Nivolumab + Ipilimumab Phase 2 Trial for Mesothelioma
Alliance phase 2 trial testing nivolumab + ipilimumab for mesothelioma. NCT05647265 is now recruiting patients.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT06362369)
7 Hills Pharma, LLC PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT06362369 is now recruiting.
Nivolumab + Ipilimumab Trial: Study for Mesothelioma
Istituto Oncologico Veneto IRCCS N/A clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT06581549 is now recruiting.
Nivolumab + Ipilimumab Phase 3 Trial (NCT06097728)
AstraZeneca PHASE3 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT06097728 is now recruiting.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT07121374)
University Hospital, Antwerp PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT07121374 is now recruiting.
Nivolumab + Ipilimumab Phase 2 Trial (NCT04400539)
University Hospital, Lille PHASE2 clinical trial testing nivolumab plus ipilimumab for people with mesothelioma. Trial NCT04400539 is now recruiting.
Pembrolizumab Trial NCT04897022 (Memorial Sloan Kettering): Phase 1 Study for Mesothelioma
Memorial Sloan Kettering Cancer Center PHASE1 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT04897022 is now recruiting.
Pembrolizumab Trial NCT05086692 (Medicenna): Phase 1/2 Study for Mesothelioma
Medicenna Therapeutics, Inc. PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT05086692 is now recruiting.
Pembrolizumab Trial NCT03556228 (VM Oncology): Phase 1/2 Study for Mesothelioma
VM Oncology, LLC PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT03556228 is now recruiting.
Pembrolizumab Trial NCT05579366 (Genmab): Phase 1/2 Study for Mesothelioma
Genmab PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT05579366 is now recruiting.
Pembrolizumab Trial NCT05732831 (Tango Therapeutics): Phase 1/2 Study for Mesothelioma
Tango Therapeutics, Inc. PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT05732831 is now recruiting.
Pembrolizumab Trial NCT06444815 (KaliVir): Phase 1 Study for Mesothelioma
KaliVir Immunotherapeutics PHASE1 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT06444815 is now recruiting.
Pembrolizumab Phase 2 Trial for Pleural Mesothelioma
Hyogo Medical University PHASE2 clinical trial testing pembrolizumab (Keytruda) for people with mesothelioma. Trial NCT06318286 is now recruiting.
Hopkins Trial: Immunotherapy Before and After Surgery Extends Mesothelioma Survival
Johns Hopkins trial shows pre/post-surgery nivolumab + ipilimumab safe for operable mesothelioma, with 28.6-month median survival.
New Review Maps BAP1 Loss in Mesothelioma
New Oncogene review maps BAP1 loss mechanisms in mesothelioma. 65% of cases involve BAP1 inactivation; EZH2 inhibitors emerge as potential targeted therapy.
Cell Therapy Shrinks Tumors in 63%
A new cell therapy achieved tumor shrinkage in 63% of advanced mesothelioma patients. More than double typical response rates.
MVdeltaC Measles Vaccine Gets FDA Orphan Drug Status for Mesothelioma
French biotech Oncovita receives FDA orphan drug designation for MVdeltaC, a modified measles virus showing 60-70% tumor reduction in mesothelioma models.
Mesothelioma Treatment Advances: 2025
2025 saw major mesothelioma treatment advances including TEAD inhibitors, bispecific antibodies, and perioperative immunotherapy. Here's the full review.
Drug Combo Achieves 60% Response Rate
A Dutch trial found two drugs achieved a 60% response rate in mesothelioma patients whose cancer returned after immunotherapy.
One Drug Halted, Another Advances
Novartis halted one experimental mesothelioma drug, but a competitor's TEAD inhibitor shows strong results in clinical trials.
Cyncado Therapeutics and ADDRI to Test TT-4 in Australian Mesothelioma Trial
An Australian trial will test Cyncado's TT-4 A2B receptor antagonist in ~50 people with mesothelioma after first-line therapy.
Mesothelioma FAQ: Common Questions
Honest answers to common questions about mesothelioma diagnosis, prognosis, treatment options, legal rights, and caregiving. Based on real patient concerns.
Drywall Workers and Asbestos Exposure
Drywall workers face mesothelioma risk from asbestos in joint compound used until 1977. Studies found 59% of workers had lung changes from exposure.
Mesothelioma Survival: 18-Year Survivor's Story
Diagnosed with peritoneal mesothelioma at 21 while pregnant, Tamron Little shares her 18-year journey and the reality of long-term survivorship.
The BAP1 Breakthrough: L-BAM Discovery
Dr. Michele Carbone's team identified L-BAM. A genetic form of mesothelioma with dramatically better outcomes than asbestos-related disease.
Steel Mill Workers and Asbestos Risks
Steel mill workers face elevated mesothelioma risk from asbestos used to protect against extreme heat. Studies show 2-4x higher disease rates.
Mesothelioma Awareness Day: September 26
September 26 is Mesothelioma Awareness Day. Learn about the history of awareness efforts, current statistics, and how to get involved.
Mesothelioma Treatment: Hopkins Immunotherapy Trial
Johns Hopkins phase 2 trial shows pre- and post-surgery immunotherapy is safe and effective for operable mesothelioma, with 28.6-month median survival.
Power Plant Workers: Asbestos Exposure Risk
Power plant workers face elevated mesothelioma rates from asbestos in boilers, turbines, and piping. Studies show 3-8x higher disease rates.
VT3989 Doubles Time Without Progression
Patients on VT3989 went 40 weeks without cancer progression. Vs. 15 weeks on standard chemo. FDA granted Fast Track status.
Hopkins: Pre-Surgery Immunotherapy Success
A Johns Hopkins trial found that immunotherapy before and after surgery extended median survival to 28.6 months, 10 months longer than average.
Trial Tests Immunotherapy Before Surgery
Baylor and Duke are testing immunotherapy before surgery for mesothelioma. Trial now enrolling operable patients.
IMPALA Trial: Light Therapy for Mesothelioma
The IMPALA trial in France is testing intrapleural photodynamic therapy combined with nivolumab for inoperable mesothelioma. Results expected mid-2026.
Textile Workers and Asbestos Exposure
Textile mill workers who manufactured asbestos cloth, rope, and fireproof fabrics face extremely high mesothelioma rates. Learn about exposure sources.
Oil Refinery Workers and Asbestos Risks
Oil refinery workers face elevated mesothelioma risk from asbestos insulation throughout refineries. Studies show 2-5x higher disease rates.
Railroad Workers and Asbestos Exposure: Occupational Hazards
Railroad workers face elevated mesothelioma risk from asbestos in locomotives, brake systems, and rail facilities. FELA provides unique legal options.
Paul Kraus: 27-Year Mesothelioma Survivor
Paul Kraus defied expectations for 27 years, becoming the world's longest-living mesothelioma survivor and patient advocate.
Teachers and School Staff: Asbestos Risk
Teachers and school staff face asbestos exposure from deteriorating building materials. EPA data shows 45,000+ schools contain asbestos.
HVAC Technicians and Asbestos Risks
HVAC workers face mesothelioma risk from asbestos in duct insulation, boilers, and old equipment. Learn about exposure sources and protection.
Dual-Target Immunotherapy Shows 52% Response
BioNTech's dual-target immunotherapy achieved a 52% response rate in people with mesothelioma. Results presented at ASCO 2025.
Genetic Factors in Mesothelioma Risk
While asbestos causes most mesothelioma, genetic factors like BAP1 mutations and Lynch syndrome can increase risk. Learn what genetics reveal.
Auto Mechanics and Asbestos: Brake Dust Risk
Auto mechanics face mesothelioma risk from asbestos in brake pads and clutches. Learn about exposure history, current risks, and protection.
Mesothelioma Diet & Nutrition Guide
Proper nutrition supports mesothelioma treatment outcomes. Learn about caloric needs, protein requirements, and managing treatment side effects.
Getting a Second Opinion for Mesothelioma
Mesothelioma is rare and often misdiagnosed. Learn why getting a second opinion is crucial and how to find specialized mesothelioma experts.
Dr. Harvey Pass: Biomarker Pioneer
Dr. Harvey Pass has led the search for mesothelioma biomarkers. Blood tests that could detect the disease when treatment is most effective.
Mesothelioma Staging: TNM System Guide
Mesothelioma staging determines treatment options and prognosis. Learn about the TNM system, survival rates by stage, and what staging means for you.
Choosing a Mesothelioma Treatment Center
Mesothelioma requires specialized care. Learn what makes a treatment center qualified and how to find the right team for your diagnosis.
Mesothelioma Caregiver Guide for Families
Caregiving for a mesothelioma patient is demanding. Learn practical tips for managing symptoms, appointments, emotions, and your own well-being.
FDA Approves Opdivo Qvantig for Mesothelioma
FDA approval of Opdivo Qvantig allows subcutaneous nivolumab delivery in under 5 minutes, compared to 30-minute IV infusions for people with mesothelioma.
Wittenoom: Australia's Blue Asbestos Ghost Town
Australia's Wittenoom mining town became the nation's deadliest industrial disaster. More than 2,000 people have died from asbestos exposure.
Paul Gleason: The Breakfast Club Actor's Mesothelioma
Actor Paul Gleason, best known as Principal Vernon in The Breakfast Club, died of pleural mesothelioma in 2006, three weeks after diagnosis.
KEYNOTE-483: Keytruda Combo Approved
KEYNOTE-483 Phase 3 trial shows pembrolizumab plus chemotherapy improves survival to 17.3 months. FDA approved September 2024 for first-line treatment.
Multimodal Mesothelioma Treatment Guide
Multimodal therapy doubles mesothelioma survival rates. Trimodal protocols, HIPEC for peritoneal, and patient selection criteria explained.
Leonard Bernstein: The Maestro's Final Years
Leonard Bernstein, creator of West Side Story and conductor of the New York Philharmonic, battled lung disease including a pleural tumor in his final years.
Dr. David Sugarbaker: Mesothelioma Pioneer
Dr. David Sugarbaker's contributions to mesothelioma surgery and training continue to shape how the disease is treated worldwide.
DENIM Trial: Vaccine Did Not Extend Survival
The Phase 2/3 DENIM trial found that dendritic cell vaccination did not extend overall survival for people with mesothelioma after chemotherapy.
Merlin Olsen: NFL Legend's Mesothelioma
Hall of Fame defensive tackle Merlin Olsen, 14-time Pro Bowler and actor, died of mesothelioma in 2010 after asbestos exposure from childhood construction work.
MARS 2: Chemo Outperformed Surgery
The landmark MARS 2 trial found that chemotherapy alone led to better survival than surgery plus chemotherapy for pleural people with mesothelioma.
ATOMIC-Meso: Quadrupled 3-Year Survival
The ATOMIC-Meso trial showed pegargiminase plus chemotherapy quadrupled 3-year survival rates in nonepithelioid mesothelioma, the most aggressive subtype.
CONFIRM Trial: Nivolumab Extends Survival
The CONFIRM trial showed nivolumab extends survival 40% in relapsed mesothelioma. Biomarker analysis reveals who benefits most.
Warren Zevon: 'Enjoy Every Sandwich'
Warren Zevon's final months remain a powerful example of facing mortality with honesty and creativity after his mesothelioma diagnosis.
SynKIR-110 CAR-T Gets FDA Fast-Track
FDA grants fast-track to SynKIR-110 CAR-T therapy for mesothelioma. Phase 1 trial recruiting at MD Anderson, Penn, and more.
CAR-T Cell Therapy for Mesothelioma
CAR-T cells target mesothelin on mesothelioma cells. SynKIR-110 received FDA fast-track in 2023. Multiple trials recruiting.
FDA OKs Opdivo+Yervoy for Mesothelioma
In October 2020, the FDA approved nivolumab plus ipilimumab as the first immunotherapy for mesothelioma, marking the first new treatment in 16 years.
Mesothelioma Immunotherapy: FDA Options
Nivolumab plus ipilimumab improves survival to 18 months. See FDA-approved immunotherapies and current clinical trials.
CheckMate-743: Immunotherapy Beats Chemo
CheckMate-743 trial shows nivolumab plus ipilimumab extends median survival to 18.1 months vs 14.1 months with chemotherapy. 3-year survival doubles.
Checkpoint Inhibitors for Mesothelioma
Checkpoint inhibitors like nivolumab and pembrolizumab release the brakes on the immune system. Learn how PD-1 and CTLA-4 blockers treat mesothelioma.
Mesothelioma Second-Line Treatment Options
When first-line chemo fails, second-line options include gemcitabine, immunotherapy combinations, and clinical trials. PEMMELA trial showed 60% response.
Mesothelioma Clinical Trials Guide
Guide to finding mesothelioma clinical trials on ClinicalTrials.gov. Active studies include CAR-T therapy, immunotherapy combinations, and targeted drugs.
FDA Approves Optune Lua for Mesothelioma
In May 2019, the FDA approved the NovoTTF-100L System (Optune Lua) for mesothelioma, the first new treatment option since pemetrexed in 2004.
TTFields for Mesothelioma: Optune Lua
Tumor Treating Fields (Optune Lua) is FDA-approved for mesothelioma. Uses electric fields to disrupt cancer cell division with minimal side effects.
Mesothelioma in Women: Survival Rates
Women with mesothelioma have 3x better 5-year survival than men. 91% of female cases are from secondary household asbestos exposure.
Mesothelioma Chemotherapy: Drugs and Response
Pemetrexed plus cisplatin extends median survival to 12.1 months. Response rates vary by cell type: epithelioid 16.5 months vs sarcomatoid 8.8 months.
Mesothelioma Misdiagnosis: 22.6% Missed
22.6% of people with mesothelioma are initially misdiagnosed. Learn common conditions it's confused with and why second opinions matter.
HIPEC for Peritoneal Mesothelioma: Survival
CRS/HIPEC achieves 53-103 month median survival for peritoneal mesothelioma. 28-year data shows 43.6% cure rate for 7+ year survivors.
Pericardial Mesothelioma: Rare Heart Cancer
Pericardial mesothelioma affects the heart lining and accounts for less than 1% of cases. Learn about symptoms, diagnosis challenges, and treatment options.
Testicular Mesothelioma: Rarest Form
Testicular mesothelioma affects less than 1% of patients but has the best prognosis. 49% five-year survival, symptoms, treatment, and outlook.
Mesothelioma Blood Tests & Biomarkers
MESOMARK blood test detects elevated SMRP levels in mesothelioma. Learn about biomarkers for monitoring and early detection research.
Mesothelioma Radiation Therapy: IMRT Guide
Radiation therapy can control tumor growth and relieve symptoms for people with mesothelioma. Learn about IMRT, when radiation is used, and what to expect.
Mesothelioma Palliative Care Guide
Palliative care improves quality of life for people with mesothelioma. Learn about symptom management, hospice eligibility, and support options.
Mesothelioma Cell Types Explained
Cell type determines mesothelioma prognosis. Epithelioid has best outcomes (~70% of cases). Learn how histology affects treatment response.
Mesothelioma Surgery: P/D vs EPP Options
Surgery can extend survival for eligible people with mesothelioma. Compare pleurectomy/decortication and extrapleural pneumonectomy options.
Mesothelioma Diagnosis: 65% Found Late
65% of mesothelioma cases are diagnosed at Stage 3 or 4. Learn how staging works, survival rates by stage, and why early detection triples survival time.
Mesothelioma Prognosis & Life Expectancy
Mesothelioma prognosis depends on stage, cell type, and treatment. Learn what factors influence survival and how to improve your outlook.
Mesothelioma Treatment Options Overview
Complete guide to mesothelioma treatment options. Multimodal treatment achieves 32-month median survival. Learn about surgery, chemo, and immunotherapy.
Mesothelioma Symptoms: Early Warning Signs
Mesothelioma symptoms often mimic common conditions. Learn the warning signs of pleural, peritoneal, and other types. Early detection improves survival.
Peritoneal Mesothelioma: 50% Survival Rates
Peritoneal mesothelioma affects the abdominal lining. With HIPEC surgery, 5-year survival reaches 47-52%. Learn symptoms, treatment, and prognosis.
Pleural Mesothelioma: Symptoms & Treatment
Pleural mesothelioma accounts for 80% of all cases. Learn about symptoms, staging, treatment options, and survival rates. 73% survive 1 year with treatment.
Mesothelioma Causes & Risk Factors
Asbestos exposure is the only proven cause of mesothelioma. Learn how asbestos fibers cause cancer, who is at risk, and the 20-50 year latency period.
What is Mesothelioma?
Mesothelioma is a rare cancer caused by asbestos. Learn about types, symptoms, causes, and survival rates from independent medical sources.
BAP1 Gene Mutation and Mesothelioma
BAP1 gene mutation increases mesothelioma risk after minimal asbestos exposure. Carriers average 7-year survival vs 12-21 months typical.